BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8767312)

  • 1. [Therapy of hypertension 1996. Effectiveness, tolerance, cost-benefit aspects].
    Rahn KH
    Med Klin (Munich); 1996 Jun; 91(6):380-3. PubMed ID: 8767312
    [No Abstract]   [Full Text] [Related]  

  • 2. A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
    Doyle J; Omvik P; Arikian S; Casciano J; Casciano R; Gonzalez MA; Arocho R
    Manag Care Interface; 2001 Mar; 14(3):82-7. PubMed ID: 11301961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacotherapy of hypertension. How much can safely be saved?].
    Anlauf M
    MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geriatric hypertension therapy: a guide to cost-effectiveness.
    Wright JT
    Geriatrics; 1988 Aug; 43(8):55-62. PubMed ID: 3136056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical economics of hypertension therapy].
    Yamazaki T
    Nihon Rinsho; 2008 Aug; 66(8):1601-4. PubMed ID: 18700564
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of hypertension--risk/benefit: excerpts of a panel discussion.
    Acta Med Scand Suppl; 1979; 628():99-100. PubMed ID: 111473
    [No Abstract]   [Full Text] [Related]  

  • 8. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies].
    Rorive G; Delporte JP
    Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economic issues and the future treatment and management of hypertension.
    Giles TD
    AAPPO J; 1994; 4(4):27-8, 30, 33-5. PubMed ID: 10150589
    [No Abstract]   [Full Text] [Related]  

  • 10. [Organizational committee shines with incompetence].
    Aumiller J
    MMW Fortschr Med; 2005 Dec; 147(51-52):59-60. PubMed ID: 16402712
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacoeconomic aspects of the treatment of essential hypertension].
    Martynov AI; GiliarevskiÄ­ SR; Ostroumova OD; Nesterova MV; Mamaev VI
    Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antihypertensive treatment. Benefits and costs].
    Jensen HA; Svendsen TL
    Ugeskr Laeger; 1993 Jan; 155(2):118-20. PubMed ID: 8421861
    [No Abstract]   [Full Text] [Related]  

  • 13. [Fully possible to reduce the costs of hypertension treatment].
    Wettermark B; Angman A; Hjemdahl P
    Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost effectiveness in the treatment of hypertension.
    Burns R
    Clin Geriatr Med; 1989 Nov; 5(4):829-40. PubMed ID: 2514038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effective analyses in the treatment of high blood pressure.
    Fletcher A
    J Hum Hypertens; 1992 Dec; 6(6):437-45. PubMed ID: 1296007
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost as a factor in the treatment of hypertension.
    Dart RA
    Contemp Intern Med; 1995 Feb; 7(2):10-4. PubMed ID: 10150334
    [No Abstract]   [Full Text] [Related]  

  • 17. Medical and cost-economy aspects of modern antihypertensive therapy--with special reference to 2 years of clinical experience with losartan.
    Hansson L
    Blood Press Suppl; 1997; 1():52-5. PubMed ID: 9285110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in medical expenditure according to drug prices.
    Ueshima H
    Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of hypertension. Between progress and cost control].
    MMW Fortschr Med; 1999 Oct; 141(42):46. PubMed ID: 10912105
    [No Abstract]   [Full Text] [Related]  

  • 20. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.